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ABSTRACT

The terrestrial organisms Streptomyces venezuelae and Rhaponticum repens produce
toxic secondary metabolites that likely function as chemical deterrents. The polyketide SV-6
from S. venezuelae and the sesquiterpene lactone repin from R. repens both produce dosedependent and selective degeneration of dopaminergic neurons. These molecules represent two
possible tools that can be used to explore chemotoxic induction of Parkinson’s disease. In the
case of SV-6, a newly isolated metabolite, total synthesis was undertaken to confirm its structure
and biological activity. The natural product was produced from methacrolein and Roche ester
starting materials that were elaborated to their respective fragments, a vinyl iodide and a
Weinreb amide. These fragments were coupled to form SV-6 and the synthesis allows for many
additional opportunities to easily generate stereoisomers and analogs for further study. In the
case of repin, previously isolated material was used as a starting material to create a biotinlabeled probe.

There were considerable challenges due to the electrophilic nature of the

compound, but a Nicolas reaction followed by copper catalyzed cycloaddition produced an
impure biotin-repin probe. Repin was also subjected to screening in multiple biological assays
which identified proteins potentially responsible for its neurodegenerative activity.
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I. BACKGROUND INFORMATION

Dopamine is the neurotransmitter most often regarded as a “reward molecule”, with its
release punctuating food consumption and sexual intercourse, as well as the use of psychoactive
drugs such as nicotine, amphetamines and cocaine1. Interestingly, diseases that reduce dopamine
production often effect movement and motor control as well as mood and behavior. In 1817,
James Parkinson described in “An Essay on the Shaking Palsy” the disease that now bears his
name2. The term “parkinsonism” is a blanket label of any condition consisting of bradykinesia
or akinesia plus muscle rigidity, tremor, or unstable posture. Increased emphasis has more
recently been placed on non-motor components of this Parkinson’s disease (PD). These aspects
may include pain, fatigue, constipation, cognitive impairment and psychosis3. The disease is
progressive and may start with a slight tremor on one side of the body. It can diminish facial
expression, vocal tone and clarity of speech. It may also cause stiffness or slowed movement 4.
Approximately 1.5% of world’s population above the age of 65 is impacted by the disease and
the number of PD sufferers is expected to reach 8.7 million sufferers by 20305.

1.1 Parkinson’s Disease
Parkinson’s disease is routinely broken into two groups, sporadic and familial cases. The
disorder was once considered to be entirely sporadic- meaning it has no genetic basis6.
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However, there have been great advances in understanding the genetic origins of the diseases. It
is now thought that roughly 10% of patients have monogenic (familial) forms of PD6. The
disease is a complex manifestation of various environmental factors in combination with some
specific genetic susceptibilities. Among the genes consistently implicated in PD development
are SNCA, LRRK2, GBA, PRKN, PINK1, PARK7, VPS35, EIF4G1, DNAJC13 and CHCHD2.
Some of these genes (SNCA, LRRK2, GBA) are considered key in development of both familial
and sporadic forms7. The discovery of these genes and their products has led to the development
of some useful genetic animal models of the disease8,9. While these models are helpful, the exact
role of genetic factors with the environment is lacking and therefore remains a great need for
chemotoxic models.

1.2 Mitochondria, Metabolism and Neurodegeneration
Mitochondria are cellular organelles which produce energy via a series of coupled
biochemical processes. Through ATP and the electron transport chain, they generate the largest
proportion of cellular energy and are common to nearly all eukaryotic cells. Mitochondria form
reticular networks in cells and density of this network varies between cell and tissue type relative
to oxidative phosphorylation-dependent energy demands.

Among those with the highest

requirements are cardiac and skeletal muscles as well as neurons10. Due to a heritage predating
eukaryotic incorporation, mitochondria bear DNA which is distinct from that of their host cells.
Human mitochondrial DNA (mtDNA) is roughly 16.6 kilobase pairs in length. This material
consists almost entirely of exons and encodes two ribosomal RNA units, 22 transfer RNA units,
and 13 proteins. The dependence of these organelles upon the eukaryotic home it resides in for
replication, repair, transcription and translation is probably at the root of many disease states. Of
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the aforementioned 13 mtDNA encoded proteins, all are subunits of oxidative phosphorylation
system and respiratory chain (OXPHOS). The inner mitochondrial membrane contains the five
OXPHOS complexes. There are about 85 protein subunits across all OXPHOS complexes and all
complexes are required for sustenance of energetic requirements11.

Figure 1: Interplay between genetic and environmental factors in PD

In addition to mutations in mtDNA, the release of and exposure to reactive oxygen species
(ROS) are considered significant drivers of the aging process (Figure 1). There are a number of
factors for which the brain—and its dopaminergic neurons—are disproportionately affected by
these insults. The brain is rich in easily oxidized fatty acids and it also has a high rate of oxygen
consumption. This intense ROS generation coupled with a lower amount of antioxidant enzymes
relative to other tissues sets the stage for numerous cellular damage scenarios to unfold.
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Dopaminergic neurons are especially susceptible to ROS damage via metabolic products of
dopamine 1.112,13.
Medical researchers now believe that this fundamental energy metabolism may have farreaching implications in disease and cellular dysfunction14. Nuclear or mitochondrial gene
mutations can have direct consequences on mitochondrial health. The overlap of genomic
susceptibility and environmental exposure may account for the incidence and variety of diseases
of mitochondrial origin that seems to be unexplained when looking at each factor individually.
Environmental exposure to cyanide and rotenone are known to inhibit mitochondrial components
complex IV and complex I

15,15b

. For example, a group of 50,000 people suffering from folate

deficiency responded to cyanide or methanol exposure with symptoms of optical neuropathy that
were similar to Leber’s Hereditary Optical Neuropathy16. Leber’s is a mitochondrial disease of
genetic predisposition.

Other diseases of mitochondrial origin include Leigh Syndrome,

Diabetes Mellitus and potentially many others. Parkinson’s Disease, while typically associated
with degeneration of dopaminergic neurons is thought to have some mitochondrial origin17,18.

1.3 Molecular Factors in Biology of Parkinson’s and Related Diseases
There are some well-known players in this denerative pathway such as α-synuclein,
Parkin and PINK1. α-Synuclein is a neuronal protein thought to contribute to Parkinson’s
through formation of soluble oligomeric aggregates known as protofibrils. While presynaptic in
origin, α-synuclein can be secreted, leading to disease propagation by seeding further
aggregation in neighboring cells.19 While the extent of α-synuclein’s role in Parkinson’s is not
entirely clear, it is thought to participate in other neurodegerative conditions collectively labeled

4

synucleinopathies. α-Synuclein which is naturally unfolded, can be phosphorylated at Ser129,
which plays some role in aggregation into Lewy bodies. Parkin, a cytosolic ubiquitin ligase, was
once implicated in this phosphorylation at Ser129, although it now thought to de-phosphorylate
at both Ser87 and Ser129, which reduces cellular damage and death in synucleopatheies20.
PINK1 (PTEN-induced putative kinase 1) aggregation occurs on the outer membrane of
damaged mitochondria and acts as a signal for their destruction. It is believed that PINK1 and
Parkin work cooperatively. PINK1 activates and recruits Parkin from the cytosol, which in turn
phosphorylates and ubiquitinates the outer membrane, initiating selective autophagy.21 In this
model, both excessive damage to these organelles by toxins (MPTP, paraquat, rotenone and
others), and the inability to clear dysfunctional mitochondria may both lead to neuronal cell
death and Parkinson’s disease.

1.4 Environmental Toxins and PD: 6-OHDA and MPTP
The two most explored toxin models for PD are 6-hydroxydopamine (6-OHDA) and 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1.2 (Figure 2). They are the oldest models
and also share some common mechanistic traits and limitations. 6-OHDA was introduced in the
late 1900s making it the first PD toxin model to be developed14. When 6-OHDA is administered
systemically, it causes destruction of sympathetic nerve terminals in the peripheral nervous
system22. Due to the chemical similarity of both 6-OHDA and the active metabolite of MPTP to
endogenous neurotransmitters, they actively cross the blood-brain barrier (BBB) via
catecholamine transporters23,24. A possible explanation for the regioselectivity of these toxins is
that midbrain neurons have the highest concentration of dopamine transporter (DAT) per cell25.
DAT presence is required for MPTP-induced toxicity, as evidenced by mice mutants with DAT
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deletions26.

To enhance the selectivity of 6-OHDA, it is sometimes co-administered with

desipramine 1.3, a selective noradrenaline reuptake inhibitor27.

Figure 2

1.5 Metabolism and Activation of 6-OHDA
The location of 6-OHDA injection into the brain directly relates to its neurodegenerative
effect. If injected into the midforebrain (MFB), non-apoptotic morphology is exhibited within
24 hours whereas protracted retrograde degeneration can take place for a window of up to three
weeks if injected into the striatum28. Striatal injection produces morphology akin to apoptic
degeneration. For this reason 6-OHDA models must be differentiated by injection site. MFB
injections lead to rapid degeneration within a few days followed by a gradual decline to near
complete lesion in five weeks29. Striatal injection causes more gradual damage in a dosedependent pattern. For this reason, it is preferred when modeling initial stages of PD30.
Toxicity initiates as the dopamine transporter releases 6-OHDA into the cell followed by
non-enzymatic auto-oxidation31. This oxidation leads to formation of superoxides, quinones and
other radical species and causes downstream damage.

This oxidative stress hypothesis is

bolstered by the fact that overexpression of glutathione peroxidase and superoxide dismutase
protect mice from 6-OHDA-induced damage32,33. In vitro analysis of the pathways of MFB and
striatally-induced 6-OHDA degeneration has been performed. MFB injection more closely

6

resembles necrotic cell death than striatal administration and can be rescued by use of a general
caspase inhibitor33. Inihibition of the c-jun-N-terminal kinase (JNK) in rats and JNK deletions in
mice have both demonstrated protective effects in MFB and striatal 6-OHDA studies,
highlighting a common pathway in both models34,35.

1.6 MPTP Discovery, Metabolism and Activation
MPTP 1.2 was discovered serendipitously at the interface of clandestine drug synthesis
and forensic chemistry. A chemistry graduate student was seeking to synthesize meperidine
analog (1-methyl-4-phenyl-4-propionpiperidine) 1.5 for personal use. Despite early successes,
he allowed the reaction temperatures elevate, generating an ester that, following metabolism,
forms an alcohol that is subject to elimination reaction and accidentally created MPTP (see
Figure 3)36.

Figure 3: Synthesis of desmethylprodine and MPTP (MP= 1-methylpiperidin-4-one, HPMP= 1-methyl-4phenylpiperidin-4-ol)

Following self-administration of this batch, he rapidly developed bradykinesia that was
alleviated with L-dopa 1.4. Subsequent forensic analysis of his labware determined these details.
Initial injection studies in mice failed to produce such dramatic symptoms. However, later
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rediscovery of MPTP across the country several years later by a similar synthetic mistake lead to
injection of the material into monkeys. This chapter confirmed the acute toxicity of MPTP in
humans while underlining important neurochemical differences between rodents and primates.
MPTP was confirmed as a chemical probe capable of producing all of the PD hallmarks of
rigidity, tremor and instability among others37.
Although MPTP was overlooked in rodents initially, much effort has gone into
developing this model. As it turns out, rats have are uniquely resistant to the effects of MPTP
whereas mice are more susceptible.

However, certain susceptibilities within mouse

subpopulations (strain, age, gender) must be taken into account when selecting a model.
Due to the popularity of the MPTP model, much has been elucidated of the pathways by
which it causes neuronal cell death. MPTP acts indirectly as a protoxin that eventually forms the
metabolite 1-methyl-4-phenylpyridinium 1.5, or MPP+ 38. Following systemic administration in
primates, the lipophilic character of MPTP allows rapid crossing of the blood-brain barrier.
Monoamine

oxidase

B

(MAO-B)

performs

oxidation

to

1-methl-4-phenyl-2,3,-

dihydropyridinium (MPDP+) is thought to take place in the glial or serotonergic cells39. From
here, MPDP+ undergoes further oxidation to MPP+, and gains access to dopaminergic neurons
via the dopamine transporter (DAT) for which it has high affinity. This role of DAT is supported
by genetic deletion and inhibition of DAT by small molecules- both measures prevent MPTP
neurotoxicty in vivo40,41. Also of note is that DAT concentrations are highest in the midbrain
cells which may explain the unique sensitivity of these cells toward MPTP-induced damage26.
As MPP+ enters neurons, it begins to accumulate in the synaptic vesicles and in the
mitochondrial matrix by passive transport. MPP+ then collects in the mitochondria, it binds to
complex I of the electron transport chain. This step of the chain allows for oxidation of NADH
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substrates and inhibits further electron shuttling steps from taking place. This also leads to a
decrease in ATP production and increased ROS production.

Meanwhile, there is an

accompanying spike in vesicular dopamine release induced by MPP+. This dopamine is subject
to auto-oxidation that acts as another source of damaging ROS42.
Both 6-OHDA and MPTP have been explored thoroughly in animal research models.
There are specific, important differences such as animal selected, and which brain region is the
target of degeneration. Despite their limitations, they represent the best explored tools available
and these limitations highlight the importance of increasing the chemotoxic toolkit for PD
research.
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II. DISCOVERY AND SYNTHESIS OF BACTERIAL METABOLITE SV-6

2.1 Discovery of a Novel Neurotoxic Metabolite from S. venezuelae
A metabolite isolated from Streptomyces venezuelae caused age-related and dose-related
degeneration of all Caenorhabditis elegans neurons, with dopaminergic neurons specifically
degenerating more rapidly. Human neuroblastoma cells were also exposed to the metabolite. In
this assay, the SH-SY5Y-derived cells in culture showed degeneration in a dose-dependent
fashion following exposure43. Initial investigations of the metabolite suggest that it causes cell
death through decreased ATP production, increased reactive oxygen species (ROS) and
modulation of mitochondrial complex I14,44. The metabolite also disrupts protein homeostasis,
ubiquitin proteasome activity and glutathione response to α-synuclein toxicity by loss-offunction of pink1 44. These molecular changes were seen in all cells of C. elegans, but due to the
high energy demands of muscle and neuronal cells, these changes were more obvious 43,14,44.
Our collaborators at the University of Alabama (Department of Biology; Tuscaloosa, AL)
have worked for some time on modeling PD in a genetically invariant hermaphroditic C.elegans
(Nematode) model. The worm has considerable evolutionary distance from humans, but bears
many important features that make it a useful for understanding PD neuropathology and also a
testing ground for potential therapies45. Beginning with work performed by Sydney Brenner in
the 1970s to understand neuromuscular development, it has since revolutionized our
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understanding of genomics, epigenetics, cell biology and aging46. The worm has only 952 total
cells, and almost a third of which are neurons, and represents the most thoroughly mapped
neuronal circuitry and cell lineage of any model species47.

Its 302 neurons retain many

important features of its mammalian counterpart such as receptors, ion channels,
neurotransmitters, vesicular transporters and other synaptic components. It is rapidly cultured
and transparent, which allows for degenerative assessment of six anterior dopaminergic neurons
using an indicator such as green fluorescent protein (GFP)48. C.elegans has been exploited for
PD research with dopaminergic circuitry consisting of a mere eight anatomically defined
neurons. The organism’s genetic loci for PD risk factors are similarly defined and are termed
“PARK”, with 21 sites currently identified.
familial/monogenic PD.

Of these, only six are connected to

These are SNCA (α-synuclein), VPS35, LRRK2, PINK1, PRKN

(Parkin), and DJ-149. C. elegans expresses all of these homologs except α-synuclein, which is a
considerable exception. However, a variety of α-synuclein overexpression experiments have
accurately modeled the progressive degenerative and motor deficits expected in PD50.
Additionally, α-synuclein misfolding can be traced by use of green-fluorescent fusion proteins
which express into the bodywall muscle cells51.
Our collaborators’ work is not the only evidence that microbial communities may
contribute to PD. A study by Sampson et al. reported the effect of “gut microbiota on regulation
of motor deficits and neuroinflammation” in a mouse PD model52. This study demonstrated a
number of interesting patterns connecting gut microbes to PD. In mice overexpressing αsynuclein, gut microbes are required to produce microglial activation and synuclein pathology.
Treatment with antibiotics ameliorated these effects, while microbial recolonization promoted
pathophysiological symptoms.

Oral administration of microbial metabolites also promoted
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neuroinflammation and motor disturbances. Finally, the mice overexpressing α-synuclein were
colonized with microbiota from either healthy or PD-affected human donors. Those mice
exposed to the microbiota from PD-affected humans displayed deterioration in motor function in
agreement with PD symptoms.

2.2 Innovation Toward a Better Chemotoxic Toolkit
Our understanding and treatment of Parkinson’s Disease (and other neurodegenerative
diseases of mitochondrial origin) has been limited by the existing animal models used to study
the disease. These animal models often require exposure to toxins such as MPTP and rotenone.
These compounds are useful, but still leave a gap in our understanding. Increasing research into
the chemical induction of PD-like symptoms is a much needed innovation not just Parkinson’s
but for other mitochondrial diseases of neurodegeneration.

Natural products provide an

interesting subset of these chemicals as they may have been preserved in the environment over
evolutionary time as a protection mechanism.

It is speculated that only 5-15% of the

Parkinson’s population stems from hereditary factors, leading researchers to look into
environmental factors (toxins, microbiota) as important contributors to disease development9.
Figure 4 shows some natural products with mitochondrial toxicity are rotenone, iromycin, repin
and the recently identified molecule SV-6 2.8 15a, 53.
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Figure 4. Mitochondrial toxins
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2.3 Discovery and Significance of SV-6
The target molecule SV-6 2.8 was isolated from a bioassay-guided fractionation and
purification. Spent S.venezuelae growth media was extracted, yielding 300 mg of crude material
that was subjected to reverse-phase liquid chromatography (RP-HPLC). To test these fractions,
they were exposed to C. elegans in an established neurodegeneration assay45.

Further

purification of this active fraction lead to isolation of one milligram of material that displayed
significant activity. This material was subjected to high-resolution electrospray ionization mass
spectrometry and nuclear magnetic resonance to generate the putative structure.
In a related study performed by our collaborators, field collections of various
Streptomyces species not limited to S. venezuelae were performed across the state of Alabama
with the goal of determining how prevalent this toxin might be (Figure 4). Samples were
collected and organized by three categories of land-use type and physiography. The first was
agricultural soils (AG) used for crops and livestock grazing.

The second was soils from

undeveloped (UD) soils with multiple tree species and dense undergrowth. The last category
was developed or urban (UR) soils near human populations but excluding lawns and landscaped
soils54.

All three soil types were collected from across the major physiographic provinces of

Alabama to represent the topographic and geologic diversity of the state (Figure 4).
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Figure 5 Colors represent the physiographic provinces and data points (•) indicate sampling locations.
(Map courtesy of the University of Alabama Cartography Lab) 54
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The study showed that Streptomyces isolates by soil type varied with “a significant difference
found in the number of isolates obtained between agricultural and undeveloped soils” while there
was no difference between isolates when compared across physiographic provinces (Figures 5
and 6).

Figure 6 “(A) Exposure to environmental isolates of Streptomyces spp. can cause significant
neurodegeneration in populations of C. elegans. (B) Streptomyces spp. isolated from agricultural soils
caused significantly more dopaminergic neurodegeneration.”54

Isolates of Streptomyces from each land use were selected and cultured where possibleapproximately half the Streptomyces species isolated did not grow in the SYZ media that was
selected to aid in production of secondary metabolites. Of those that did grow successfully,
supernatants were collected and assessed in the neurodegeneration C. elegans model system.
From this group, 28.3% the Streptomyces spp. isolates (51 of 180 strains) produced
dopaminergic neurodegeneration in C.elegans versus 0.4% in the control group used in this study
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(E.coli extracts). When activity was tracked back to land use type there were more isolates from
agricultural and undeveloped soils with neurodegenerative activity compared to urban soils
(Figure 7).

Figure 7 “(A) Comparison of the average number of isolates obtained from dilutions of 0.25 g of
agricultural (AG), undeveloped (UD) and urban (UR) soils. (B) n = 60 for each land use. Columns with
the same letters are not significantly different from one another (Fisher’s exact test, p < 0.01).”54

This led the authors to conclude that there was a neurodegenerative compound(s) being
produced in the soil responsible for the Parkinsonian-like symptoms seen in rural populations
that were not previously accounted for by other environmental factors such as herbicide,
fungicide and pesticide exposure54. Furthermore, the authors hypothesize that there is a common
mitochondrial toxicant across many of these Streptomyces isolates. The authors believe that SV6 may be a common toxicant and total synthesis help in understanding its ecological distribution
and mechanism of action.
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2.4 Structure of SV-6
SV-6 2.8 is a 13-membered linear polyketide that bears structural similarities to other
metabolites from S. venezuelae. Figure 8 below highlights the structural similarity of SV-6 with
methynolide 2.10 and pikromycin 2.11. Of note is the 10-hydroxy group that is shared across all
the structures and may be a product of PikC oxidation instead of polyketide synthase
metabolism55. Pik pentakide 2.13 is a common biosynthetic precursor to both methynolide and
pikromycin56. It is important to note that the stereochemistry of SV-6 in this figure is only
hypothetical and based on the known metabolites from S.venezuelae. Only following the total
synthesis of SV-6 and comparison to the isolated metabolite can this structure be confirmed.
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Figure 8
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2.5 Polyketide Synthase and the Biosynthetic Origin of SV-6
While a vast diversity of structures are enabled by strict implementation of polyketide
synthase machinery, there are even more possible variations enabled by incorporation of
alternate starter or extender units (Figure 9).

Figure 9 General biosynthetic format of polyketide pathway responsible for aromatics, macrolides and
fatty acids57.

In addition to malonyl and acetyl-CoA units, Figure 10 shows the PKS can also use propionylCoA units which can be converted into methylmalonyl-CoA extender units by addition of CO2
by propionyl-CoA carboxylase. This allows for methyl groups to be installed between carbonylbearing units. Some bacteria can also incorporate iso-fatty acids in the PKS pathway. These
branched chain fatty acids are otherwise used to maintain membrane fluidity.
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They are

generated from branched chain amino acids and serve as alternate PKS starter units. Leucine,
isoleucine and valine lead to isovaleryl-CoA, 2-methybutyryl-CoA and isobutyryl-CoA
respectively (Figure 10).

Figure 10 Incorporation of branched motifs into PKS pathway products57.

In the case of SV-6 it seems probable that isobutyryl-CoA was used as a starter unit followed by
incorporation of multiple methylmalonyl-CoA units. In addition to the variety of loading and
extender units and subsequent reductions and dehydration steps, there is potential for other
21

tailoring steps following PKS release, such as decarboxylation, Pik oxidation and to form
macrocyclic lactone rings. In the case of SV-6, there is a disparity in carbon count and acetate
incorporation pattern. It is possible that the parent unit was decarboxylated then subjected to
redox transformations to result in the proposed structure for the isolated natural product (see
Figure 11).
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Figure 11 General biosynthetic hypothesis for PKS assembly of SV-6. Main assembly (top), followed by
post-PKS release tailoring steps (bottom).
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2.6 Initial SV-6 Synthesis Plan: Andrade and Breit Fragments
To date, neither the structure nor the synthesis of the target molecule SV-6 has been
published. Although the synthesis will be new, the plan is to rely on well-established methods
for producing polyketides. The final compound could be produced in a convergent fashion by
coupling two fragments such as a vinyl iodide and aldehyde (Scheme 1) fragment A 2.13 and
fragment B 2.14, followed by oxidation and deprotection (Fig.2).

Our confidence in this

approach was based on the successful syntheses of similar polyketides tridesmethyl
telithromycin, and vittatalactone by the groups of Andrade and Breit, respectively58,59,60.
Scheme 1 Disconnection between fragments A and B

Scheme 2 Initially planned fragment A synthesis

Fragments A and B may be derived from enantioselective alkylations of simple α,βunsaturated aldehyde starting materials methacrolein 2.15 and crotonaldehyde 2.22 with

24

diethylzinc. In the case of fragment A, the alcohol 2.16 could be oxidized to the epoxide 2.17
using Sharpless asymmetric epoxidation61. This is followed by ring opening with pivalic acid to
selectively protect the least hindered position59. At this point, the 1,2 diol 2.18 can be protected
with an acetal 2.19. The pivalate group can be removed using methyllithium, and then oxidized
to the aldehyde 2.21. Takai-Utimoto olefination will be used to finish fragment A 2.13.
Scheme 3 Initially planned fragment B synthesis

The synthesis of Fragment B 2.14 continues from a distinct allylic alcohol than fragment
A. First, a Steglich esterification with ortho-diphenylphosphanylbenzoic acid (o-DPPBA) 2.24
is performed, and a portion of this product 2.25 is retained for a later step (Scheme 3, step g).
Stereospecific addition of the branched bromide to the ester in a copper-assisted Grignard
reaction (Figure 12) followed by ozonolysis concludes the synthesis of fragment B. This
iterative approach using o-DPPB esters has proven effective in longer polyketides by Breit and
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co-workers60. Cleavage of the double bond with ozonolysis (or alternative method), followed by
reduction and Appel reaction leads us to an intermediate 2.26 to be reacted with previously
generated o-DPPB ester 2.2562.

Figure 12 Breit's proposed mechanism of stereoselectivity

Fragment A and fragment B would be connected via a Nozaki-Hiyama-Kishi reaction (Scheme
4). This reaction has previously been proven effective in the synthesis of other polyketides such
as telithromycin, palytoxin, and halichondrin B59,63,64.
Scheme 4
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2.7 Enantioselective Oganozinc Alkylations of Aldehyde Building Blocks
It was envisioned that both starting materials could be derived from enantioselective
alkylations of simple enone starting materials methacrolein 2.15 and crotonaldehyde 2.22 with
diethylzinc (Scheme 5). This enantioselective counterpart to the Grignard addition reaction is
based on the pioneering work of Noyori, which established the utility of β-amino alcohols such
as DAIB 2.32 (Scheme 6) to enantioselectively control addition of diorganozincs to aldehydes65.
Scheme 5

Diaorganozincs were held to be an ideal alkyl donor due to their sp-hybridized linear
geometry. The alkyl-metal bond was relatively nonpolar, but it could be bent to induce reactivity
toward carbonyls upon perturbation by external ligands. The formation of stable alkylzinc
alkoxide tetramers in hydrocarbon solvents following release of anionic ligands could also be
leveraged as a driving force for the reaction (Scheme 6). Addition of diethylzinc addition to
aromatic aldehyde substrates fared best in yield, enantiomeric excess and reaction time. Alkyl
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aldehydes and longer alkyl groups in the organozinc agents both performed poorly.

α,β-

unsaturated aldehydes performed somewhere in the middle. Methacrolein and crotonaldehyde
were both explored in this initial report, but not optimized.
Scheme 6

Later, Nugent and coworkers at Bristol-Myers Squibb performed parallel synthesis
techniques to more thoroughly understand the structure-activity relationships of β -amino alcohol
ligands in asymmetric organozinc alkylations66. They too focused on benzaldehyde 2.32 as their
test substrate. In a follow-up study it was determined that a tertiary amine substructure bearing
piperidinyl or morpholinyl rings was optimal in all cases67.

N-terminal and O-terminal

substituents were both deemed critical and simplified amino alcohols performed abysmally.
Introduction of a phenyl group to N-teminal position dramatically improved enantioselectivity to
83% while introduction of a cyclohexyl group increased enantioselectivity to 67%. The
combination of both features proved yielded a new ligand 2.30 that could be produced in two
steps.

In this case, catalyst loading of 5% both aromatic and α,β-unsaturated aldehydes

(including methacrolein) performed well while alkyl aldehydes still performed poorly.
In a recent update to this method by Myers and co-workers, the conditions for this
reaction were optimized.

In this case, they needed to produce large quantities of (R)-2-

methylpent-1-en-3-ol 2.16 from methacrolein 2.1568,69. In their work, they were able to modify

28

addition protocol which resulted in both a reduction in catalyst loading and a reduction in
transfers of pyrophoric diethylzinc. They found that by adding diethylzinc to a suspension of
catalyst followed by slow addition of methacrolein followed by aqueous-acidic workup they
could also recover their ligand in high purity. They also changed the solvent from hexanestoluene (2:1) to pure hexanes. Using catalyst loading of 1% and reaction temperature of 0 oC,
they attained product in 76% yield with 99% ee. With these studies from Noyori, Nugent and
Myers as a guide, we would attempt to extend this method to crotonaldehyde as a substrate using
a tert-butyl morpholine ligand to produce an analogous ethylation product, hex-4-en-3-ol 2.23.
Scheme 7

In regard to SV-6, the work began by synthesizing the ligands to be used (Scheme 7).
Next, these were to be applied to the synthesis of fragment B because the starting material,
crotonaldehyde was much less expensive than methacrolein ($0.20 versus $6 per milliliter). This
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would allow me to test the ligand-directed diethylzinc reaction on a more affordable starting
material. Both ligand 2.30 and 2.31 were made in two steps. This was followed by asymmetric
ligand-directed alkylation of crotonaldehyde with diethyl zinc and 2.31 based on the work of
Noyori and Myers70,68. At small scale this reaction seemed to have some impurities. It was
initially performed on a scale too small too effectively perform vacuum distillation on. Initial
attempts at purification with column chromatography were challenging due to the small size and
nonpolar nature of the compound. Spectra indicated some impurities but there was uncertainty
as to if they were oxidation products (unlikely), solvent impurities or residual chromatography
solvents. Only after scaling the reaction up was it apparent that the reaction had produced a
mixture of products (Scheme 8), with our intended product being the major component.
However, this mixture was not separable further by column chromatography or distillation.
After realizing this fact, the ligand-directed alkylation was abandoned.
Scheme 8

2.8 Overhauled SV-6 Synthesis Route
Due possibility for rearrangements and associated loss of optical purity, a new route was
adopted with some advantages.

It would also be safer- no longer requiring large-scale
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diethylzinc and ozonolysis reactions.

Existing procedures for many intermediates were

detailed58,56. This route would also simplify access to isomers and analogs of SV-6 (Figure 13).
The commercially available Roche ester starting materials contains a stereogenic center that will
appear in the final product. The only downsides were is that this route did not have as many
opportunities to explore reaction development and the Roche ester starting material is more
expensive.

Figure 13: Modular access to various stereoisomers and analogs

2.9 Fragment A Synthesis: Cossy Fragment
Following the mixed results of the zinc alkylation, it was decided to use a route that was
based on the best documented chemistry possible (Scheme 9). There was a related route taken
by Cossy et al. that also ended with haloolefination to yield the final product58. It began with a
reaction of methacrolein with an ethyl Grignard reagent. This formed the racemic mixture of
(E)-hex-4-en-3-ol enantiomers. These were effectively resolved using Sharpless conditions61,71.
Silyl protection of the allylic alcohol followed by dihydroxylation formed a mixture of
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diastereomers that were chromatographically inseparable. These were carried forward though
oxidation to the aldehyde, haloolefination and deprotection. Following deprotection of the silyl
ether, the mixture became easily separable on silica gel.

Treatment of the diol with

dimethoxypropane and pyridinium p-toluenesulfonate yielded the protected vinyl iodide that
would be used to couple with fragment B.

Scheme 9

2.10 Fragment B Synthesis: Roche Ester and Pseudoephedrine Chiral Auxiliary
Synthesis of pseudoephedrine propionamide 2.53 and TBS-protected iodide 2.57
proceeded smoothly before encountering problems (Scheme 10). First, the chiral Roche ester
was purchased from Sigma-Aldrich, protected with a tert-butyldimethylsilyl protecting group.
The protected ester was reduced with DIBAL to the alcohol which was displaced to the iodide
under Appel conditions.
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Scheme 10

By far the most troublesome reaction of the entire SV-6 synthesis was the alkylation of
(R,R)-pseudoephedrine propionamide 2.53 with the TBS-protected iodide 2.57. The related
reactions were reported in the literature with yields up to 95% so this difficulty was
unforeseen72,73,56. Moisture sensitivity was expected for this reaction but even with careful
application of anhydrous techniques the yield plateaued at 15%. The purified product matched
data published for the compound but attempts to increase yield were met with failure. Different
batches pre-prepared LDA and LiHMDS were used to no success.

Diisopropylamine was

repeatedly distilled over activated molecular sieves and n-butyllithium sources where repeatedly
titrated.

The reaction duration and temperatures were varied as were equivalents of reagents

used in the reactions. Both pseudoephedrine propionamide 2.53 and protected iodide 2.57
starting materials were resynthesized numerous times to no avail. Test reactions using benzyl
bromide instead of the protected iodide 2.57 were also performed to narrow down the cause of
the problem.
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Scheme 11

This well-supported transformation presented a surprising challenge, and was temporarily placed
on hiatus while I synthesized fragment A. After returning to this reaction, it was rerun with a
previously opened bottle of LDA which surprisingly yielded 80%.

The reaction was

immediately repeated at larger scale using the same batches of every reagent, resulting in a yield
of 75% (Scheme 11). Although this reaction worked well enough to move forward, there was
never a scientifically satisfying conclusion as to why it did not work initially.
The first plan was to use alkyllithium reagents to displace the chiral auxiliary and then
reduce the carbonyl. This exact reaction is unreported, but its closest analogs use t-butyllithium,
phenyllithium and n-butyllithium, with maximum reported yields of 71%, 98% and 95%
respectively

74,75,76

. At this point, the Clemmensen approach was reappraised with an eye to

possible issues such as epimerization (Scheme 12).
Scheme 12
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Other routes were all considered and the step-count and reaction yields from similar
systems in the literature were all compared before finding a suitable replacement.

In the

selected approach (Scheme 13), I opted to first reduce the amide auxiliary to the primary alcohol
2.61. It could then be transformed to a tosylate 2.62, which would be displaced with a copperassisted alkyllithium. The ammonia-borane reduction worked well but the tosylation had yields
of 30-40%. The solvent was changed from dichloromethane to pyridine, improving conversion
to 99%. The resulting product 2.60 was deprotected with tetrabutylammonium fluoride and
oxidized with nickel (II) chloride and commercial bleach (sodium hypochlorite)77.
Scheme 13

Unfortunately, the yield for the nickel (II) chloride oxidation was less than 15%. It was a very
complex TLC and the main polar product was isolated and matched expected molecular weight
when analyzed with ESI mass spectrometry.

It was not characterized further.

Instead of

optimizing a reaction with limited literature support, the reaction was abandoned77. I attempted
an alternative oxidation using TEMPO, sodium hypochlorite and sodium chlorite78.

This

reaction went smoothly and after achieving a yield of 77% (Scheme 14), the reaction scale was
increased and the resulting material was taken forward to the next step.
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Scheme 14

Water soluble carbodiimide (EDC) in DMF with standard amide coupling conditions was used
to form the Weinreb amide product 2.65 (Scheme 15). The reaction yielded 45% but without
any more acid starting material, this was all that would be used for the remaining steps of the
synthesis.
Scheme 15

The second to last step was a coupling reaction between the fragments 2.13 and 2.14
(Scheme 16). A vinyl lithium species from vinyl iodide 2.13 and t-butyllithium is prepared in
situ to attack the Weinreb amide fragment 2.14. This was performed on ten-milligram scale with
a yield of 46%.
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Scheme 16

Six milligrams of the protected enone product 2.29 was subjected to acidic deprotection
conditions (Scheme 17) using a mixture of tetrahydrofuran and aqueous hydrochloric acid at
room temperature. This last step proceeded slowly, but it was ultimately successful with 95%
yield.
Scheme 17

2.11 Future Work
The construction of the proposed SV-6 structure has been completed to supply six
milligrams for spectroscopic analysis and biological assay. This material was transferred to the
original investigators and will be compared to the spectra of the natural product. The initial
synthesis can be repeated to generate more material if needed for biological analysis. In the
event that the structures do not match, computational studies in combination with synthesis of
isomers may be used to ascertain the configuration of the natural product79. The potential for
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diversity is an advantage of the second route that cannot be understated (Figure 14). By using
the same experimental procedures outlined herein, it is possible to generate countless isomers
and unnatural analogs for the study of structure-activity relationships80. The figure below shows
just a few examples of compounds that can be generated by following these procedures but only
substituting commercially available reagents.

Different enantiomers of Roche ester,

pseudoephedrine diisopropyl tartrate (DIPT) can be used to influence the stereochemistry of the
branched alkyl units (C-4 and C-6) and hydroxyl group (C-10 and C-11). Different groups can
be substituted at the C-4 position by use of different pseudoephedrine amides. In this case, any
number of anhydrides or acyl chlorides may be used to generate chiral amides in a single
chromatography-free step.

Substitution of different groups can be added to C-3 position but

replacing the isopropyllithium used for SV-6 with other organollithiums or Grignard reagents.

Figure 14
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III. CHEMICAL MODIFICATION OF REPIN

3.1 Rhaponticum repens and Toxic Parkinsonism in Horses
Russian knapweed or Rhaponticum repens (L.) Hidalgo of the family Asteraceae is the
most recognized toxic plant contributor to equine nigropallidal encephalomalacia (also called
toxic equine parkinsonism or “chewing disease”)81.

It has been previously referred to as

Centaurea repens or Acroptilon repens. It is an invasive perennial plant species that is native to
Eurasia but was brought to the United States in the early 1900’s. It bears broad, oblong lower
leaves leaves but toothed upper leaves. The plant has and thin, stiff, pithy stems and stands
erect, with the potential to grow up to one meter in height. It bears urn shaped flowers that vary
from pink to purple in color. Once past maturity, these flowers fade into a straw color. The
seeds are also a straw or ivory color, oval in shape and 2 mm wide, 4 mm long and 1 mm thick
(Figure 15). Both the seeds and the stems are covered with fine hairs. The plant has invasive
character, leading to infestations in fields. In the case where they do not entirely dominate an
area to the point of monoculture, they can suppress the growth, size and number of plants it
shares location with. According to Watson as of 1980 they were capable of reducing grain
density by 28-75%. Plant extracts of R. repens have demonstrated allelopathic inhibitory effect
of crop plants. It seems to only require tillable soil, with some preference for saline or alkaline
soils. Russian knapweed is robust in its ability to survive without regard for other species of
plant it is surrounded by (or lack thereof). It is this co-habitation with crop plants that is thought
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to be responsible for its spread south and east, most likely from sale and distribution of hay
contaminated with Russian knapweed seeds82.

The majority of these R. repens traits are

common to Centaurea solistialis, with some difference in flower morphology. For instance,
C.solistialis has yellow flowers with sharp thorns extending from the base of the buds.

Figure 15 Images of Rhaponticum repens (A) full plant (B) seeds (C) flowering tops in hand for scale (D)
single flower83.

40

Figure 16 Distribution of Russian knapweed in the United States83

3.2 Toxic Effects of R. repens
Cordy first reported that horses in the northern and central region of California were beset
by a neurological disorder linked to the consumption of Russian knapweed and yellow star
thistle. It had been previously identified by local veterinarians as “chewing disease” or “yellow
star thistle poisoning”65. According to this initial report, there was always a sudden onset to the
symptoms which included impairment of eating and drinking. Some animals displayed complete
inability to eat or drink while others might be “dropping feed from the mouth, [partially unable]
to move the material back to the molars, or some difficulty swallowing”65. Eating was typically
affected more than drinking, hence the name “chewing disease”. Also common was a fixed
expression and tongue protruding from between incisor teeth which indicated paralysis of the
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facial musculature. Of note were changes in the behavior of horses, they often stood motionless
or with a drowsy pose. This was accompanied by aimless, abnormally slow or awkward walking
which deteriorated to a wobbling or shuffling gait in later stages. Initially a parasitic or viral
cause of these symptoms was considered, but further anatomical investigation of horse tissues
were ruled inconsistent with either hypothesis.

Eventually, this constellation of movement

impairments combined with the presence of neuronal legions was termed “equine nigropallidal
encephalomalacia” (ENE)84. Despite the sudden onset of ENE, animals must consume 59-71%
of their body weight before these symptoms manifest.

3.3 Structure of SQLs from R. repens
Due to the allelopathic and toxic activity of the R. repens plant, it has been the target of
thorough phytochemical examinations. The focus of this work is on terpenes although alkaloids,
flavonoids, tannins, polyacetylenes and glycosides have all been isolated from the plant. Studies
of volatile components by Buttery and Binder demonstrated that SQLs comprise between 50%
and 90% of the plant material by weight. Specifically, there were 58% of aggregate volatiles in
buds, 56% in blooms, and over 89% in leaves and stems85,86. In a series of studies led by Stevens
for the USDA, a number of SQLs were identified from Centaurea solstitialis, particularly
noteworthy among these structures are the presence of many chlorohydrins (3.3, 3.7, 3.8, 3.11)
products from the opening of epoxides and picrolide 3.2, which bears p-hydroxybenzoyl
methylene moiety on 4-position of the A ring (Figure 17)87.
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Figure 17
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3.4 Collection of Plant Material and Isolation of Repin
The plant material (R. repens) was collected by Dr. Gunatilaka (September 2002) and Dr.
Rimoldi (July-August 2004 and May 2007) in Riverside, California. It was collected in a
somewhat developed semiurban area (near a golf course). This location was selected based on
previous positive identification and collections on the same plot of land. Mature flowering
plants were collected and dried and voucher specimens were deposited at the University of
California at Riverside herbarium.
A variety of methods have been used for isolation of SQLs from Centaurea species.
These approaches involve the use of many different combinations of solvents and stationary
phases or treatment of extracts with lead (II) acetate to facilitate removal of chlorophyll 88.
Rimoldi et al. have used various methods89.
Method A
The first method begins with hexane extraction for 24 h, then two acetone extractions for
2 h each. These acetone extracts were combined, evaporated and subjected to vacuum liquid
chromatography (VLC) using a ethyl acetate/hexane gradient (30% ethyl acetate increasing to
100%). Following analysis and combination of subfractions, repin was isolated after another
round of column chromatography.
Method B
Aerial plant material was macerated in hexanes for 24 h followed by two 48 h acetone
extractions. This extract was evaporated then reconstituted in anhydrous ethanol. The ethanolic
solution was slowly treated with a 5% aqueous solution of lead (II) acetate which formed a
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precipitate that was stirred for 24 h before vacuum filtration. This filtrate was evaporated and reextracted into anhydrous dichloromethane. Extracts were dried over sodium sulfate, evaporated
and subjected to VLC using a ethyl acetate/hexanes gradient (50% ethyl acetate increasing to
100% followed by 60:40 isopropanol/ethyl acetate).

Subfractions from the 75:25 EtOAc-

hexanes were rich in repin and were subjected to recrystallization from ethyl acetate.
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3.5 Biosynthesis of Sequiterpenes
There is a vast array of terpenoids present across the plant kingdom whose structures
range from simple to incredibly complex. All these structures can be traced back to only a
couple of simple biosynthetic intermediates- either mevalonic acid (MVA) and methylerythritol
phosphate (MEP)57.

Figure 18
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The conventional names for these structures fall into terms determined by the size of their carbon
skeletons. Some discrepancy between named category and final carbon count may be attributed
to loss of carbons by decomposition of a larger terpene structures or late-stage addition of small
units. The overall structure is represented by (C5)n. With this system, the family of terpenes is
subclassified as hemiterpenes (C5), monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20),
sesterterpenes (C25), triterpenes (C30), and tetraterpenes (C40), followed larger isoprene polymers
such as rubbers (Figure 18). These units are rarely seen as simple linear polymers and instead
often undergo a number of oxidations, rearrangements and combinations with intermediates of
acetate, peptide and shikimate pathways to form their isolated products57.
MVA is formed by the fusion of three molecules of acetyl-coenzyme A. The eventual
decarboxylation and dehydration of mevalonic acid diphosphate (MVAPP) yields isopentyl
phosphate (IPP). Figure 19 displays enzyme-mediated isomerization of IPP to DMAPP creates
the system where SN1-mediated loss of diphosphate anion creates stabilized cation that will
serve as the electrophilic partner to the nucleophilic terminal alkene of IPP. These two initially
combine to form geranyl diphosphate (GPP), which can now act as an electrophile to another IPP
unit57.
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Figure 19

This iterative process continues for another cycle and the result is farnesyl diphosphate (FPP). It
is important to note that stereospecific proton loss is responsible for E-stereochemistry of the
double-bond. This stereochemical outcome is an important factor in the subsequent creation of
intramolecular carbon-carbon bonds on the E,E- farnesyl scaffold. FPP is a key intermediate in
the formation of multicyclic terpenes, including the sesquiterpene lactones. Loss of diphosphate
from farnesyl-PP generates a cation facilitating E1 elimination to form (+)-germacrene A. This
is followed by a series of enzymatic oxidations using NADPH, to generate parthenolide (Figure
20).
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Figure 20: Biosynthesis of medicinally valuable parthenolide

Parthenolide is a secondary metabolite with well-known cytotoxic activity90.

But

parthenolide represents only one example of the potential products produced from the germacryl
cation intermediate. Figure 21 below shows the diversity of structures generated from three
products of the germacryl cation intermediate. Fermacrene, costunolide and parthenolide serve
as the biosynthetic precursor to many biologically active sesquiterpenes including repin, the
subject of our group’s research. What we understand of the biosynthesis of terpenes is the
product of many years of study using isotopic labeling and biochemical experimentation57.
However, the exact path of repin’s synthesis in Centaurea solstitialis remains unclear.
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Figure 21 Structural diversity generated from germacrene, parthenolide and costunolide
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3.6 Modification to Repin
There are numerous cytotoxic compounds in R. repens, but the exact toxin and mode of
action are not entirely understood. Repin 3.15 is prevalent in the plant and a definite contributor
to neurotoxicity but outward indicators of degeneration are not completely consistent with the
established models of Parkinson’s disease. The primary aim of this work has been to create
derivatives of repin to act as molecular probes to determine its protein target.
Preliminary work in the Rimoldi lab has identified the portions of the molecule that seem
to contribute to the neurotoxic activity and those that do not (Figure 22)89. The next stage of our
investigation is to create a biotin-linked conjugate which will be used to identify the molecular
target(s) of repin.

Figure 22

The early work focused on using esterification reactions to directly bind the secondary
alcohol of repin to the carboxylic acid of biotin. Unfortunately due to the multiple sensitive
electrophic groups of repin, these attempts at esterification were met with failure. The primary
issue with all these approaches was that nucleophilic reagents can attack repin directly at these
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sites.

Non-nucleophilic bases can catalyze intramolecular attack while acidic conditions

facilitate carbocationic rearrangements.

Table 1

However, esterification using the smaller acrylic acid 3.18 was successful. This now provided a
handle for olefin cross-coupling chemistry (Scheme 18). A complementary biotin allyl 3.19
amide was produced successfully, but the Grubbs cross-coupling attempts did not work.
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Scheme 18

The Huisgen 1,3-dipolar cycloaddition (Scheme 19) is known to be extremely
chemoselective and performs well in complex mixtures including biological systems91. The
regiochemistry can be controlled depending on whether copper or ruthenium is used to catalyze
the reaction. The system we planned to use is Cu(I) catalyzed alkyne-azide cycloaddition
(CuAAC) as it creates the stable triazole with the linker and repin scaffold oriented trans to from
each another.
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Scheme 19

3.7 Alternate Route: Nicholas and Click Cycloaddition
Recently, a modification of the Nicholas reaction has been reported by the groups of
Harki and Brummond in which the nucleophile is the limiting reagent, reducing the capacity for
nucleophilic attack onto reactive scaffolds92. This method has shown utility in attaching alkyne
ligation handles onto serine alcohols, cysteine thiols, tyrosine phenols, pyrrolidine nitrogens of
proline, as well as amino and carboxy groups of amino acids. Sesquiterpene lactones bearing
similar functionalities such as Melampomagnolide B 3.23 and a guaianolide analog 3.25 (Figure
23) have also been successfully modified using this method. One foreseeable problem with this
approach is the possible steric interference of adjacent epoxide.
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Figure 23 Examples of sesquiterpene lactones screened by Harki and Brummond92

3.8 Nicholas Reaction: Success and Failure
The Nicholas reaction was attempted on repin as a substrate and after many failed
attempts, we produced the propargyl ether product 3.21 of interest. Over two steps, the yield was
approximately 15% (10mg), and was never fully purified away from a co-eluting impurity
(Scheme 20). The reaction was repeated at larger scale in order isolate enough material for the
CuAAC reaction with biotin-azide and subsequent biological studies.

In these subsequent

reactions, it never fared better in terms of yield or purity. The addition of the propargyl group
was evident on NMR and high-resolution mass spectral data matched that of our intended
product.
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Scheme 20

3.9 Copper-catalyzed Alkyne-Azide Cycloaddition
As the supply of isolated repin dwindled, the limited amount of the propargylated
material that remained was taken forward for CuAAC reactions (Scheme 21).

These

cycloadditions proved more challenging than expected (Table 2). The stability of the repin
scaffold under acidic CuAAC conditions was first tested using repin instead of the propargylated
material. Following this, the reaction was attempted under various conditions (~1mg scale) with
varying success before scaling up.
Scheme 21
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The reaction yields were not quantified, only monitored by TLC and ESI-MS for consumption of
starting materials and formation of product 3.28. When using CuI as a copper (I) source,
transition of solution from clear or yellow to bright blue corresponded with the consumption of
starting material. Despite this useful indicator of reaction progress, this reaction did not behave
in the same manner when scaled up. This is likely due to inaccuracy of measuring reagents in
those test reactions. After moving to CuSO4/ sodium ascorbate conditions, the reaction worked
well and scale up was more successful.

Table 2

It was immediately obvious that the product of interest had almost the same retention
factor on silica as the biotin-PEG3-azide starting material 3.27. The material was subjected to
preparative thin layer chromatography, but the material produced was not pure. This material
was subsequently subjected to HPLC, but the two peaks were not separable, possibly due to the
weak UV absorbance of the components of the mixture in the range of the UV detector. The
same material was subjected to LC-MS analysis, where product was clearly identified. However,
the purity was approximated to be 30%-50%, with uncertainty due to variable levels of
ionizability between components of the mixture. NMR analysis of the product showed presence
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of biotin, polyethylene glycol and repin sections of the molecule but also with areas of
unidentifiable impurities.

3.10 Additional Target Screens for Repin
The narrow goal of this project was project was to create a biotin tagged version of repin.
The overarching goal of this project has been to better understand the molecular mechanisms at
work behind repin’s unique toxicity. The failure to produce analytically pure biotinylated repin
is only one aspect of a project in which there were some noteworthy revelations. Large scale
screening of protein targets has become increasingly practical and multiple lines of investigation
were pursued. Repin was submitted multiple different screens including a broad, multiplexed
serine protease assay (ENPLEX) and a panel of kinases (KinomeScan)93,94.

Despite the

possibility that a compound bearing multiple electrophilic sites may not show selectivity against
enzymes, this was not the case.
Repin was screened against a total of 158 enzyme targets and only showed activity at two
different targets (APPENDIX I). Of the 158 targets, 119 were serine hydrolases and 39 were
kinases. Repin showed no interaction with the set of serine proteases that included HTRA2,
which is correlated with essential tremor and PD95. Of the 39 kinases selected based on literature
support correlating them to dopaminergic signaling, mitophagy, PD, or neurodegeneration, only
two targets were to be inhibited: GRK3 and LKB1. LKB1 regulates the ability of presynaptic
mitochondria to clear calcium by regulating the density of a Ca2+-selective ion channel on
mitochondria’s inner membrane.

This LKB1-regulated calcium clearing also controls

neurotransmitter release from excitatory synapses on cortical axons96. LKB1 demonstrates a role
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in autophagy, a pathway that is the only route to degrade protein aggregates that cannot be
processed by the proteasome. This autophagy pathway is of particular importance in autosomal
dominant PD (α-synuclein and LRRK2 associated)97. The other hit, GRK3, is a kinase that
phosphorylates dopamine G protein-coupled receptors following activation by a ligand. This
activation creates a high-affinity interaction between the G proteins and arrestin- a feedback loop
that leads to deactivation and receptor degradation. The interplay of GPCRs, G proteins, arrestin
and GRKs regulates striatal dopamine signaling and can lead to dyskinesia that is typical of
PD98. While much remains to be understood, there are now two previously unreported protein
targets for repin to guide further studies. Almost as important are the negative results from the
119 proteases targets, highlighting the incredible selectivity that is possible with sesquiterpene
Michael acceptors such as repin99.

3.11 Future Work
Studying the molecular mechanism of repin’s toxicity has been an object of our attention
for some time. Despite not purifying a pure biotinylated product, this work represents a way
forward. Another path considered but never attempted was a modification of repin to the azide.
This seemed much more risky due to the nucleophilicty of the azide anion involved, but it may
be

facilitated

by

activation

with

Schwartz’s

reagent/

zirconocene

hydrochloride.

Hydrozirconation can be followed with displacement with a nucleophile, such as halogen or
azide (Figure 24). This may be further complicated by iodination prior to azide substitution.
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Figure 24

The modification of repin is all predicated on the amount of natural product available to attempt
said modifications. Further synthetic studies would all require more repin to be isolated from
Knapweed extracts or plant material. Purification of the biotin-repin from its mixture may be
enabled by semi-preparative LC-MS.
Biological studies have failed to produce a complete picture of how repin manifests its
toxicity (APPENDIX I). A streptavidin pulldown assay may still provide a missing piece of
evidence to tie some of these activities together. It is possible that such an assay using the crude
biotinylated material could yield this information if HRMS-based proteomic analysis could
differentiate between various covalent adducts.
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EXPERIMENTAL

General
All reagents were purchased from Sigma-Aldrich, Acros Organics or Alfa Aesar.
Chromatography solvents were purchased as certified A.C.S. grade from Fisher Scientific.
Acros extra dry solvents over molecular sieves were used for all reactions.

Thin layer

chromatography (TLC) was performed on Merck silica gel 60 F254 aluminum sheets.

To

visualize TLCs, both UV light and staining reagents (phosphomolybdic acid, ceric ammonium
molybdate, and potassium permanganate) were used. Flash chromatography was performed
using standard grade silica gel particle size of 32-62 μm from Sorbent Technologies. 1H NMR
and 13C NMR spectra were recorded using Bruker 400 or 500 MHz instruments. Low resolution
mass spectral data was acquired using Waters ZQ with electrospray ionization (ESI) conditions.
Optical and specific rotation were measured using a Rudolph Autopol IV polarimeter.
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This method was adapted from a procedure by Myers et al68. A 3000ml flame dried three neck
with flask with magnetic stir bar was removed from oven and flame dried under vacuum and
filled with argon three times. After cooling, (S)-3,3-dimethyl-2-morpholinobutan-1-ol ligand
(1.54 g, 8.24 mmol, 0.02 eq.) was added followed by 300 mL of anhydrous hexane. After ligand
was fully dissolved in hexanes, the flask was cooled to 0oC. At this point, a solution of Et2Zn in
hexanes (800 mL, 1.0 M, 800 mmol, 1.94 eq.) was added via cannula, immediately causing a
dense white vapor to form the receiving vessel. This solution was stirred for 30 min at 0oC, then
crotonaldehyde (33.6 mL, 412 mmol, 1 eq., freshly distilled) was added over 90 minutes by
syringe pump.
After 3 h, magnetic stir bar was carefully removed and stirring was changed to an overhead,
mechanical apparatus.

Ice-chilled HCl (850 mL, 3 M) was added dropwise via pressure

equalizing addition funnel. A thick white precipitate formed during the addition, but eventually
dissolved near the end of the quenching step. The entire biphasic mixture was added to a 4000
mL separating funnel and layers were separated. The aqueous layer was extracted (2 x 500 mL),
then combined and washed with brine (500 mL). The washed solution was dried over Na2SO4
and filtered. This bulk volume of the filtrate was removed by rotary evaporator at a pressure of
~40 Torr and temperature of 10oC. The clear oil concentrate was transferred to a 250 mL roundbottom flask using diethyl ether to quantitate transfer. Remaining solvent was removed at
atmospheric pressure using a short-path distillation head and heating at 90oC (oil bath). This
bath was then removed; distillation flask was cooled to 23oC. Pressure was then lowered again
to ~40 Torr and receiving flask was placed in a ice-water bath. Distillation resumed as the oil
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bath reached 90oC and product distilled at a temperature of oC at ~40 Torr. The resulting clear
liquid weighed 31 g (yield 75%). Enantiomeric excess was not determined as the NMR data
showed presence of major impurities. Side product produced was consistent with literature
values for the constitutional isomer hex-3-en-2-ol100.
1

H NMR (400 MHz, CDCl3) δ 5.68 – 5.53 (m, 2H), 5.50 – 5.36 (m, 1H), 4.20 (p, J = 6.4 Hz,

1H), 3.89 (q, J = 6.6 Hz, 1H), 2.07 (s, 1H), 1.99 (p, J = 7.4 Hz, 1H), 1.65 (dd, J = 6.4, 1.5 Hz,
3H), 1.48 (ddt, J = 16.9, 13.9, 7.2 Hz, 2H), 1.19 (d, J = 6.3 Hz, 2H), 0.94 (t, J = 7.5 Hz, 2H), 0.84
(d, J = 14.9 Hz, 3H).
13C NMR (101 MHz, CDCl3) δ 134.07, *133.16, *132.33, 126.62, 74.33, *68.73, 30.03, *25.03,
*23.32, 17.56, *13.34, 9.69. (asterisks denote impurity)
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Acetal-protected vinyl iodide (“Fragment A”) was produced wholly in accord with the published
synthesis by Cossy58. Spectra were found to be in agreement.

(R,R)-Pseudoephedrine propionamide was produced wholly in accord with the published
synthesis by Myers73. Spectra were found to be in agreement.

(1R,2S)-1-cyclohexyl-2-morpholino-2-phenylethan-1-ol (“Ligand 1”) was produced wholly in
accord with the published synthesis by Nugent67. Spectra were found to be in agreement.

(S)-3,3-dimethyl-1-morpholinobutan-2-ol (“Ligand 2”) was produced wholly in accord with the
published synthesis by Hayashi101. Spectra were found to be in agreement.
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Using an adapted method from Sherman, starting material iodide was dried azeotropically with
benzene twice before use56. To an oven-dried 300 mL round bottom flask was added lithium
chloride (6.69 g, 157.73 mmol, 12eq.). This vessel was then iteratively flame dried under
vacuum and back-filled with argon gas for five cycles. While cooling, an oven-dried 50ml pearshaped flask was charged with pseudoephedrine propionyl amide (4.65 g, 21.03 mmol, 1.6 eq.).
After careful heating under vacuum and backfilling with argon for three cycles followed by
cooling, dry THF (40ml) was added via cannula.
50mL was then added to the 300mL flask containing lithium chloride and the resulting slurry
was allowed to stir for 30 minutes. This flask was cooled -78oC. Lithium diisopropylamine
solution (21ml, 42.06 mmol, 3.2 eq. of ACROS, 1.7M in THF/n-heptane/ethylbenzene) was
added and maintained at -78oC. At this time, the contents of the 50mL flask were transferred via
cannula to the 300mL flask. The resulting solution was stirred for 1 h at -78°C, 30 min at 0°C,
and 10 min at RT before it was cooled to 0 °C. Protected alkyl iodide 2 was dissolved in 15mL
THF and added dropwise followed by an 8mL THF wash. Solution was allowed to warm to
room temp and stirred for 12 h. The reaction was quenched with saturated NH4Cl (60 mL), and
poured into a 250mL separatory funnel containing H2O (100 mL), and the aqueous layer was
extracted 3x with CH2Cl2. The combined organic extracts were washed with brine and filtered
through a sodium sulfate plug, which was then rinsed 2x with CH2Cl2. Concentration and flash
chromatography: EtOAc/Hexanes (3:7) afforded a white, waxy solid (4 g, 9.81 mmol, 75%
yield). Spectral data matched that of previously published synthesis72.
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To a 100mL flame-dried round bottom flask under argon was added 20ml dry THF. The flask
was cooled to 0oC. Lithium diisopropylamine solution was added (8.1 mL, 16.2 mmol, 4.4 eq. of
ACROS, 1.7M in THF/n-heptane/ethylbenzene) and allowed to stir 3 min. Borane-ammonia
complex (468 mg, 14.7 mmol, 4 eq., 97% Sigma-Millipore) was added quickly in one portion.
Solution was stirred 15 min at 0oC, then stirred 15 min at RT, then returned to 0oC. The amide
(1.5g, 3.7 mmol, 1 eq.) dissolved in 10 mL THF and added followed by a 10 mL THF wash.
Solution was warmed to RT with a water bath, stirred 4.5 h then cooled to 0oC and cautiously
quenched with 40 mL (chilled) 1N HCl then stirred at RT for 30 min. Reaction mixture was
added to separatory funnel and extracted 4x 50mL Et2O. Organic phase was washed with 50mL
1N HCl, 50mL 1M NaOH, and 100mL brine. Organic phase was dried over MgSO4 and solvent
was removed under reduced pressure (rotovap bath temperature >10oC.) Flash chromatography:
Et2O/Hexanes (4:6) afforded a clear liquid (780 mg, 3.16 mmol, 86% yield). Product material
matched previously published spectroscopic data55.
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To a solution of alcohol (628 mg, 2.55 mmol, 1 eq.) in pyridine (2.5 mL) was added paratoluenesulfonyl chloride (971 mg, 5.1 mmol, 2 eq.) and DMAP (47 mg, 0.382 mmol, 0.15 eq.) at
0°C.
The reaction mixture was allowed to warm and was stirred for 3 h at RT before it was quenched
with HCl (1.0 N, 7 mL) and extracted with ethyl acetate (2× 10 mL).
The combined organic extracts were washed with saturated Na2CO3 solution (2 × 7 mL) and
brine (1 × 7 mL), dried with anhydrous Na2SO4 and filtered. Concentration and flash
chromatography: (pentane/ethyl acetate, 9:1) afforded 1.01 g of tosylate as clear oil (99%).
Spectral data matched that of previously published synthesis102.
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To a flame-dried, argon filled flask was added CuI (1.62 g, 8.51 mmol, 3.3 eq.), followed by two
vacuum-argon cycles. Flask was cooled to 0 °C, 15mL of dry Et2O was added, followed by
25mL a 0.7 M solution of isopropyllithium (ACROS in pentanes; 17.27 mmol, 6.7 eq) via
cannula.
After 45 min, the mixture was cooled to -78°C and treated with tosylate (1.03 g, 2.57 mmol, 1
eq.) in 3 mL of dry Et2O, followed by 3ml Et2O wash. After 3 hr, the reaction mixture was
quenched with 50mL of a 4:1 mixture of NH4Cl (sat.)/NH4OH (29%) at 0 °C, extracted with
Et2O, washed with brine and dried with MgSO4. Concentration and flash chromatography:
(100% hexanes) afforded 525 mg of alkylated product as clear oil (75%).
1

H NMR (CDCl3, 400 MHz) δ 3.45 (dd, J = 9.7, 5.1 Hz, 1H), 3.33 (dd, J = 9.7, 6.7 Hz, 1H), 1.72

– 1.51 (m, 3H), 1.34 – 1.20 (m, 2H), 1.14 – 1.05 (m, 1H), 1.00 – 0.81 (m, 22H), 0.04 (s, 6H).
13

C NMR (CDCl3, 101 MHz) δ 68.46, 46.91, 41.83, 33.27, 29.91, 27.91, 26.13, 26.13, 26.13,

25.38, 23.86, 22.2, 20.70, 17.82, -5.1, -5.20.
HRMS: Calculated [M+Cs]+ calculated for C16H36OSiCs: 405.1590 m/z; found 405.1793 m/z.
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To a stirred solution of protected alcohol in 3.5 mL THF at 0oC was added tetrabutylammonium
fluoride solution (ACROS 1M in THF; 2.5 mL, 2.5 mmol, 1.9 eq.). The cooling bath was
removed and the reaction was stirred at RT overnight. Concentration under reduced pressure and
flash chromatography (100% hexanes to 100% CH2Cl2; Rf 0.36 in 100% CH2Cl2) afforded
188mg of product (90%). Spectral data matched that of previously published synthesis60.
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To a solution of alcohol in CH3CN (8 mL) and phosphate buffer (8mL, pH 7.0, 100 mM) were
subsequently added NaClO2 (310 mg, 3.42 mmol, 6.3 eq.), NaClO (1.55 mL; store-bought
Clorox brand, 8.5% chlorine content) and TEMPO (7 mg, 0.046 mmol, 0.09 eq.) at room
temperature. After being stirred for 1 h, the pH value of the reaction mixture was adjusted to 3
with 2M HCl.
Volatiles were removed in vacuo; the aqueous residue was extracted with diethyl ether (2 x 30
mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous
Na2SO4, concentrated in vacuo. Flash chromatography: 15% ethyl acetate/hexanes (Rf: 0.34,
20% ethyl acetate/ hexanes) afforded a clear, liquid product with a minty aroma (72 mg, 77%
yield).
1

H NMR (CDCl3, 400 MHz): δ 10.17 (brs, 1H), 2.67 – 2.62 (m, 1H), 1.79 – 1.69 (m, 2H), 1.61 –

1.56 (m, 1H), 1.24 (d, J = 6.5 Hz, 3H), 1.21 – 1.01 (m, 4H), 0.98 – 0.84 (m, 11H).
13

C NMR (CDCl3, 101 MHz) δ 182.79, 45.49, 40.30, 36.37, 27.09, 23.91, 22.19, 21.21, 18.72,

16.81.
HRMS: Calculated [M-H]+ calculated for C10H20O2: 171.1385 m/z; found 171.1359 m/z.
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To an ice-cooled and stirred solution of trimethylheptanotic acid (57 mg, 0.33 mmol, 1 eq.), was
added N,O-dimethylhydroxylamine hydrochloride (34 mg, 0.35 mmol, 1.05 eq), and
triethylamine (0.04 mL, 0.35 mmol, 1.05 eq) in DMF (6mL) HOBt (51 mg, 0.38 mmol, 1.15 eq)
and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73 mg, .38 mmol, 1.15 eq)
were added. The mixture was stirred at room temperature for 15 h.
At this point, reaction was diluted with toluene, washed with 1N aq. HCl followed by saturated
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.

Flash

chromatography: 1:9 ethyl acetate/hexanes to 1:4 ethyl acetate/hexane yielded 32 mg of amide
(45% yield).
1

H NMR (CDCl3, 400 MHz): δ 3.69 (s, 3H), 3.17 (s, 3H), 1.78 – 1.59 (m, 2H), 1.50 – 1.37 (m,

1H), 1.15 – 0.89 (m, 7H), 0.83 (m, 9H).
DEPTQ-135 NMR (CDCl3, 101 MHz) δ 61.55, 46.92, 41.83, 32.77, 28.51, 25.25, 25.25, 23.53,
22.39, 20.25, 18.31.
HRMS: Calculated [M-H]+ calculated for C12H25NO2: 214.1807 m/z; found 214.1966 m/z.
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To a stirring solution of vinyl iodide (10 mg, 0.046 mmol, 1 eq.) in dry Et2O (0.75mL) at -78oC
was added t-BuLi (ACROS 1.7M in pentane) dropwise. After stirring 45 minutes at -78oC, a
solution of amide (30 mg, 0.102 mmol, 2.2 eq.) in 0.5ml Et2O was added quickly followed by a
0.5mL rinse. Reaction mixture was then warmed to -42oC (acetonitrile and dry ice bath) and
stirred 1hr.
After this time, the reaction mixture was diluted with Et2O and quenched by addition of saturated
aqueous NH4Cl solution at 0°C. The solution was extracted with Et2O; the organic layers were
combined, washed with brine, dried over MgSO4 and concentrated under reduced pressure.
Flash chromatography: 1:9 diethyl ether/pentanes afforded a clear liquid product (7 mg, 46%).
Note: Some solvent signals and dibutylhydroxytoluene (from diethylether) were present in NMR
spectra. Due to the unknown volatility of this compound, it was only exposed to high-vacuum for
a brief period.
1

H NMR (CDCl3, 500 MHz): δ 6.78 (d, J = 15.5 Hz, 1H), 6.43 (d, J = 15.5 Hz, 1H), 3.82 (t, J =

6.6 Hz, 1H), 2.81 (dt, J = 13.6, 6.8 Hz, 1H), 1.71 – 1.60 (m, 3H), 1.53 – 1.49 (m, 5H), 1.45 –
1.37 (m, 11H), 1.25 (s, 3H), 1.13 – 0.92 (m, 11H), 0.88 – 0.79 (m, 11H).
13

C NMR (CDCl3, 126 MHz) δ 203.82, 146.93, 127.26, 86.24, 77.16, 46.88, 42.79, 41.40, 28.47

(2C), 28.28, 26.62, 25.26 (2C), 24.83, 23.59, 23.49, 22.25, 17.32, 11.40.
HRMS: Calculated [M+Cs]+ calculated for C20H36O3Cs: 457.1719 m/z; found 457.1695 m/z.
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To a 20 mL scintillation vial was added 5 ml of 1:1 THF/1N HCl and stirred at RT for 18 h.
After 24h, 60 µL 3N HCl was added and reaction was monitored. After 24 additional hours, 40
µL 3N HCl was added and the reaction was monitored for disappearance of starting material.
After 24 additional hours, the reaction was quenched with NaHCO3. This mixture was extracted
with ethyl acetate (6 x 5 mL) and washed with brine. Flash chromatography: CH2Cl2 to 1:6 ethyl
acetate/CH2Cl2 yielded 5 mg of product (95% of theoretical yield).
1

H NMR (CDCl3, 400 MHz): δ 6.86 (d, J = 15.6 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 3.4 (dd, 8, 4

Hz, 2H), 2.81 (dt, J = 13.6, 6.8 Hz, 1H), 2.56 (s, 1H), 2.02 (s, 1H), 1.75 – 1.50 (m, 6H), 1.50 –
1.39 (m, 2H), 1.34 (s, 3H), 1.27 (d, J = 14.4 Hz, 1H), 1.08 (d, J = 6.9 Hz, 3H), 1.00 (t, J = 7.4 Hz,
3H), 0.88 – 0.78 (m, 10H).
13

C NMR (CDCl3, 101 MHz) δ 204.10, 148.02, 126.90, 79.72, 75.71, 46.83, 42.87, 41.17, 28.44,

25.27, 25.16, 24.92, 23.57, 22.28, 20.21, 17.37, 11.14.
HRMS: Calculated [M+Cs]+ calculated for C17H32O3Cs: 417.1406 m/z; found 417.1575 m/z.
[α]D21= +13.5 (c 0.67, CHCl3)
IR (neat) 3373, 2958, 2929, 1675
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Prepare silica column for flash chromatography before or while starting reaction procedure.
Remove round-bottom flask from the oven, fill with argon, cover and cool to room temperature
on bench. Dissolve 16μL propargyl alcohol in 1.5mL of anyhdrous CH2Cl2. Weigh and transfer
cobalt carbonyl into a separate flask. Add propargyl alcohol/CH2Cl2 solution to cobalt carbonyl
containing flask and stir at RT for 1.5 hours.

Dissolve 50mg of repin into 2.3mL anhydrous

CH2Cl2. Cool reaction flask to 0oC. Add repin solution followed by dropwise addition of BF3etherate. Stir only 10 minutes, add 1ml saturated NaHCO3. Stir one minute before addition of
(4ml) water.
Extract 3x with CH2Cl2. Dry on MgSO4, filter and evaporate onto Celite under reduced pressure.
Separation on silica (0% to 30% gradient of ethyl acetate/hexanes). Main spot elutes at 30%
ethyl acetate, and solvent is immediately removed before carrying Co2(CO)6-alkyne intermediate
rapidly to the next step. To 15mg cobalt complex is added 1.5 mL acetone is added 60mg of
ceric ammonium nitrate. Reaction is allowed to stir 10 minutes (or until consumption of starting
material is complete). The reaction was diluted with distilled water and diethyl ether. The
mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer
was extracted with diethyl ether (3x). The combined organics were dried over magnesium
sulfate, filtered, and concentrated under reduced pressure rotary evaporation. Yields over two
steps ranged between 5%-15%.
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1

H NMR (CDCl3, 400 MHz) δ 6.21 (d, J = 3.5 Hz, 1H), 5.54 (d, J = 3.1 Hz, 1H), 5.21 – 5.09 (m,

3H), 4.94 (s, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.34 (d, J = 4.3 Hz, 1H), 3.17 (dd, J = 14.4, 5.0 Hz,
3H), 2.81 (d, J = 5.9 Hz, 2H), 2.45 (d, J = 2.4 Hz, 2H), 2.03 (s, 1H), 1.60 (s, 4H), 1.24 (s, 3H).
13

C NMR (CDCl3, 101 MHz) δ 169.99, 168.80, 141.13, 137.36, 122.29, 118.99, 82.58, 77.16,

76.53, 75.48, 75.11, 65.87, 56.76, 53.88, 52.93, 49.51, 47.79, 45.89, 36.24, 36.00, 17.61, 17.49.
HRMS:
[M+NH4]+ calculated for C22H28O7N: 418.1866 m/z; found 418.1808 m/z.
[M+Na]+ calculated for C22H24O7Na: 423.1866 m/z; found 423.1845 m/z.
[2M+Na]+ calculated for C44H48O14Na 823.2942 m/z; found 823.2908 m/z.
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The procedure was adapted from biotin labeling of sterols103. To a solution of propargyl repin
(7mg, 1 eq) and biotin-PEG3-azide (8mg, 1.03 eq) in tetrahydrofuran (0.08 mL), t-butanol (0.04
mL) and water (0.02) was added a solution of copper(II) sulfate pentahydrate (.62mg, 0.22 eq in
0.01 mL of water) and a solution of sodium ascorbate (1.5 mg, 0.44 eq in water (0.01 mL),
respectively. After stirring at 30oC for 36 h, the solvent was removed by evaporation and residue
was extracted by ethyl acetate (2 x 5 mL). Combined organic extracts were washed with water
(3 x 5 mL), saturated aqueous NaCl (2 × 10 mL) and dried over anhydrous Na2SO4. The residue
was

then

purified

by

preparative

thin

layer

chromatography

(15:8:4:1

ethyl

acetate/chloroform/methanol/water). This gave impure biotin labeled repin (4mg, 27%) as a
white solid.
HRMS: [M+Na]+ calculated for C40H56N6NaO12S: 867.3575 m/z; found 867.3570 m/z.
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General Description of Repin Kinase Assay
The assay used for repin (KINOMEscanTM by DiscoverX), does not require ATP and allow
reporting of thermodynamic interaction affinities instead of IC50 values which are often used
and can be influenced by ATP concentration.The kinase may bind the ligand in either an
orthosteric (in active site) or allosteric fashion (indirectly).

Both cases may inhibit enzymatic

activity and potentially downstream signaling associated with the kinase.

In in the figure

below(A), target kinases (squiggly, blue) are allowed to interact with immobilized ligand
(orange) in the absence of test compound. Test compounds (gray) either interfere with kinase
binding to immobilized ligands (B) or do not interfere (C). The compounds and unbound kinase
is washed away and the amount captured is compared to control samples and quantitatively
measured using qPCR of the associated DNA label for each target protein94.
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Experimental details of Kinome Scan Assay
For the majority of the assays, kinase-tagged T7 phage strains were grown in 24-well blocks in
an E. coli host (derived from the BL21 strain). After being grown to log-phase, the E.coli was
infected with T7 phage (multiplicity of infection = 0.4) and incubated with shaking at 32°C until
lysis (90-150 minutes). The lysates were and filtered (0.2µm) to remove cell debris. The
remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for
qPCR detection.
Affinity resins for kinase assays were generated by treating streptavidin-coated magnetic beads
with biotinylated small molecule ligands for 30 minutes at room temperature.
These beads were then blocked with excess biotin and washed with blocking buffer (SeaBlock
by Pierce Biotechnology), 1 % BSA, 0.05 % Tween 20, 1 mM DTT) to wash unbound ligand
and to reduce non-specific phage binding. Binding reactions were assembled by combining
kinases, liganded affinity beads, and test compounds in 1x binding buffer (20 % SeaBlock, 0.17x
PBS, 0.05 % Tween 20, 6 mM DTT). Test compounds were prepared in DMSO as 40x stocks
and directly diluted into the assay. All reactions were performed in 384-well plates in a final
volume of 0.02 ml. The assay plates were incubated at room temperature for 1 hour with
shaking. At this point, the affinity beads were washed buffer consisting of 1x PBS, 0.05 %
Tween 20. The beads were then re-suspended in elution buffer (1x PBS, 0.05 % Tween 20, 0.5
µM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30
minutes. The kinase concentration in the eluates was measured by qPCR94.
The compounds were screened at 1 micromolar concentration. The results were reported as
“percent of control” (% Ctrl) . To calculate percent of control, the following formula was used:
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Where:
test compound = compound submitted by our lab (repin)
negative control = DMSO (100% control)
positive control = control compound (0% control)
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Results of KinomeScan assay (DiscoverX - Eurofins)
Table 3
DiscoveRx Gene Symbol
ABL1-nonphosphorylated
ABL1-phosphorylated
AURKA
CDK5
CHEK1
CSNK2A2
DYRK2
ERK1
ERK2
GRK1
GRK2
GRK3
GRK4
JNK1
JNK2
JNK3
LKB1
LRRK2
LRRK2(G2019S)
MEK1
MEK4
MKK7
MLK2
MLK3
p38-alpha
p38-beta
p38-delta
p38-gamma
PKN1
PRKCD
PRKCE
PRKCH
PRKCI
PRKCQ
PRKD1
PRKD3
PYK2
RIPK1
RIPK2

Entrez Gene
Symbol
ABL1
ABL1
AURKA
CDK5
CHEK1
CSNK2A2
DYRK2
MAPK3
MAPK1
GRK1
ADRBK1
ADRBK2
GRK4
MAPK8
MAPK9
MAPK10
STK11
LRRK2
LRRK2
MAP2K1
MAP2K4
MAP2K7
MAP3K10
MAP3K11
MAPK14
MAPK11
MAPK13
MAPK12
PKN1
PRKCD
PRKCE
PRKCH
PRKCI
PRKCQ
PRKD1
PRKD3
PTK2B
RIPK1
RIPK2
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% Control
71
81
100
99
98
100
83
100
100
91
94
57
83
100
93
100
66
91
100
98
100
100
100
92
100
100
100
100
100
89
98
100
87
77
100
97
100
100
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EnPlex Assay Results and Description (Bachovchin Lab)

“Purified enzymes are coupled to Luminex microspheres, with a different bead color for each
enzyme. Multiplexed bead complexes are incubated with a compound before being treated with a
biotinylated activity-based probe and a streptavidin R–phycoerythrin conjugate (SASAPE). The
mixtures are scanned on a Luminex flow cytometer, where one laser detects the bead color
(enzyme identity) and a second laser detects the R-phycoerythrin signal (enzyme activity).
Changes in absorbance are due to interruption of SAPE interaction by an inhibitor93.”
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Figure 25: EnPlex Assay Results: Repin showed no activity pattern across any protease.
Positive DPP4 hit (ValboroPro, left lane) compared to repin (listed as MJC-1-21, right lane).
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APPENDIX II: SPECTRAL DATA

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

VITA
EDUCATION
Ph.D., Medicinal Chemistry
University of Mississippi, University, MS

May 2018

M.S., Pharmacognosy
University of Mississippi, University, MS

Dec. 2013

B.S., Biochemistry & Molecular Biology
Mississippi State University, Mississippi State, MS

May 2007

RESEARCH POSITIONS
Graduate Research Assistant (John Rimoldi)
Aug. 2013 – Present
The University of Mississippi, Department of Medicinal Chemistry, University, MS
- Total synthesis of a polyketide implicated in dopaminergic neurodegeneration
- Derivatization of sesquiterpene lactone implicated in dopaminergic neurodegeneration
- Synthesis and design synthetic cannabinoid receptor ligands
- Scale-up synthesis of Sigma receptor ligand for in vivo
- Synthesis and design of prolylcarboxypeptidase enzyme inhibitors
Graduate Research Assistant (Ikhlas Khan/ Amar Chittiboyina)
Aug. 2010 – Aug. 2013
The University of Mississippi, Department of Pharmacognosy, University, MS
 Synthesis, isolation and structure elucidation of intermediates en route to psychoactive
natural products mesembrine and mesembrenone
 Extraction and isolation of natural products using chromatography
 Structure elucidation of terpenes, alkaloids and sterols from Eurycoma longifolia Jack
using IR, MS, 1D and 2D NMR
 In silico screening of natural products for phosphodiesterase 5 activity
Graduate Research Assistant (Jennifer Irvin, Steve Whitten)
May 2009 – July 2010
Texas State University, San Marcos, TX
 Synthesis, isolation and structure elucidation of monomers for use in construction of
electroactive polymeric materials
 Bacterial culture, expression and isolation of p53 protein
 Thermodynamic ensemble modeling of p53 protein using Fyrestar (RedStorm) software
Undergraduate Research Assistant (Nara Gavini, Lisa Wallace)
Aug. 2003 – Dec. 2006
Mississippi State University, Mississippi State, MS
 Used microbial culture and molecular methods (PCR, blotting) studying nitrogenase
fusion proteins, effects of gold nanoparticle exposure to Azotobacter vinelandii
 Extracted, isolated genetic material from Platanthera (Orchidaceae) species using
molecular methods
 Analyzed DNA sequence information using Sequencher and Mr.Bayes software to
evaluate phylogenetic classifications of orchids

120

TEACHING POSITIONS
University of Mississippi, University, MS
Department of Medicinal Chemistry
 Pharmacogenomics Teaching Assistant
 Tutor for pharmacy students for medicinal, organic and biochemistry coursework
Texas State University, San Marcos, TX
Department of Chemistry and Biochemistry
 Instructor for general (II), analytical and organic (I) chemistry lab sections
 Chemistry tutor for undergraduate general and organic chemistry

2014

2009-2010

PUBLICATIONS
Design and Synthesis of Icariin Analogues as PDE-5 inhibitors (Oxford ICSB 2011 Poster)
In silico-screening of natural products for potential phosphodiesterase (PDE) 5A1 inhibitors
(Oxford ICSB 2014 Poster)
‘Use of broad molecular screening assay to determine selectivity of prolylcarboxypeptidase
inhibitors’ (MALTO 2016 Podium Presentation)
‘Synthesis and evaluation of dual-acting opioid and neuropeptide FF Ligands’ (AAPS 2017
Poster)
‘Sceletorine A and B, two unprecedented dimeric alkaloids from Sceletium tortuosum’ (Organic
Letters, Submitted)
‘Progress towards the enantioselective total synthesis of a novel metabolite’ from Streptomyces
venezuelae” (Poster, 255th ACS National Meeting 2018)
‘Total synthesis and toxicological evaluation of Streptomyces venezuelae Metabolite SV6’ (In
Preparation)
‘Identification and characterization of the protein targets of neurotoxic sesquiterpene lactone
repin” (In Preparation)
LEADERSHIP POSITIONS
President of Medicinal Chemistry Journal Club
Director of Graduate Affairs, Graduate Student Council

2012 - 2016
2012 - 2013

OTHER POSITIONS, AWARDS AND DISTINCTIONS
Member, Rho Chi (Pharmaceutical Sciences Honors Society)
2017
Instrumentation Assistantship, Elemental Analysis (CHN)
2016
Division of Organic Chemistry Travel Award (ACS National Meeting, San Diego)
2016
Graduate Assistant to Vice Chancellor of Research (Dr. Alice Clark)
2013 - 2015
Graduate Representative, Chancellor’s Standing Committee on Libraries
2012 - 2013
Pharmacognosy Senator, Graduate Student Council
2010 - 2012
PTCB Certified to work as Pharmacy Technician (Certified in Texas)
2009

121

